| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $10.00 | Buy | H.C. Wainwright |
| 3/7/2025 | $15.00 | Sector Outperform | Scotiabank |
| 11/25/2024 | $24.00 → $5.00 | Buy → Neutral | BofA Securities |
| 10/24/2024 | $20.00 | Buy | UBS |
| 10/1/2024 | $25.00 | Outperform | Wedbush |
| 9/25/2024 | $21.00 | Buy | Truist |
| 7/25/2024 | $24.00 | Buy | BofA Securities |
| 5/9/2024 | Overweight | Cantor Fitzgerald |
SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13D/A - Perspective Therapeutics, Inc. (0000728387) (Subject)
First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 40 patients enrolled through end of April 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumorsEnrollment ongoing for VMT01, a first-in-class MC1R targeting potential new medicine, with first patient treated at a new monotherapy dose level in April 2025, following the first patient
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate and be available for one-on-one meetings with investors at the following upcoming investor conferences. Bank of America Global Healthcare ConferenceDate: Tuesday, May 13, 2025Format: Fireside ChatTime: 11:35 a.m. – 11:50 a.m. PT / 2:35 p.m. – 2:50 p.m. ETLocation: Las Vegas, NV 2025 RBC Capital Markets Global Healthcare Conference Date: Tuesday, May 20, 2025Format: Fireside ChatTime: 3:05 p.m. - 3:30 p.m
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was treated with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Patients are being selected for [212Pb]PSV359 targeted alpha particle therapy by SPECT imaging with [203Pb]PSV359. "We are excited to explore a new avenue to treat cancers expressing FAP-α wi
SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company's [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation as detailed below at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3, 2025 in Chicago, Illinois. ASCO plans to release further details for regular abstracts on May 22, 2025 at 5:00 PM EDT. PresenterAbstract TitlePresentation DetailsThorvardur Halfdanarson[212Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR
SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 12, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Compan
SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), as monotherapy in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. Patients in this cohort are receiving [212Pb]VMT01 at 1.5 mCi as monotherapy. Initial results from the earlier monotherapy cohorts were previously presented at the 21st International Congr
SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. 24th Annual Needham Virtual Healthcare Conference - 1x1s OnlyDate: Monday, April 7, 2025Location: Virtual Stifel Virtual Targeted Conference Forum – Company PresentationDate: Tuesday, April 8, 2025 Time: 3:30-3:55 p.m. ETLocation: Virtual About Perspective Therapeutics, Inc.Pe
On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 30 patients enrolled through end of February 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumorsAchieved first-in-human combination dosing of a PD-1 inhibitor with one of our potential new medicines, with recent dosing of VMT01 in combination with nivolumabIND cleared for PSV359, which targets FAP-α, associated with multipl
SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. Patients in this cohort are receiving [212Pb]VMT01 at 1.5 mCi in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb as Opdivo®. Patien
SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. TD Cowen 45th Annual Health Care Conference – Company PresentationDate: Monday March 3, 2025Time: 11:10 a.m. - 11:40 a.m. ETLocation: Boston, MA Barclays 27th Annual Global Healthcare Conference – Fireside ChatDate: Tuesday, March 11, 2025Time: 3:30 p.m. - 3:55 p.m.
H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00
Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00
BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously
UBS initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $20.00
Wedbush initiated coverage of Perspective Therapeutics with a rating of Outperform and set a new price target of $25.00
Truist initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $21.00
BofA Securities initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $24.00
Cantor Fitzgerald initiated coverage of Perspective Therapeutics with a rating of Overweight
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO). "In less than 18 months, Perspective has delivered initial clinical data for two new potential medicines based on its next generation targeted radiopharmaceutical technology platform,
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total mark
Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period end
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be p
SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research ("SMR"), being held on October 10-13, 2024 in New Orleans, Louisiana. The title of the poster presentation for the Phase 1/2a study of [212Pb]VMT01 is "First in Human Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Melanoma (MM)." "We are looking forward
First Quarter 2024 Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 GAAP fully diluted net income per share of $1.87, compared to GAAP fully diluted net loss per share of $0.04 in first quarter 2023. Adjusted fully diluted net income per share of $1.69 compared to adjusted fully diluted net income per share of $1.47 in the first quarter 2023The Company increases full year 2024 net revenue and earnings guidance and provides guidance for the second quarter 2024 BEDFORD, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fig
SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. Previously operated by Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company, this 11,500 square foot facility, located in Somerset, New Jersey, has operated in compliance with both Part 212 and Part 211 of Ti
SD - Perspective Therapeutics, Inc. (0000728387) (Filer)
10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
DEFA14A - Perspective Therapeutics, Inc. (0000728387) (Filer)
DEF 14A - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
EFFECT - Perspective Therapeutics, Inc. (0000728387) (Filer)
POS AM - Perspective Therapeutics, Inc. (0000728387) (Filer)